- Home
- JCSE vs APRE Comparison
JCSE vs APRE Comparison
Compare JCSE & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCSE
- APRE
- Stock Information
- Founded
- JCSE 1999
- APRE 2006
- Country
- JCSE Singapore
- APRE United States
- Employees
- JCSE N/A
- APRE N/A
- Industry
- JCSE Miscellaneous manufacturing industries
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JCSE Consumer Discretionary
- APRE Health Care
- Exchange
- JCSE Nasdaq
- APRE Nasdaq
- Market Cap
- JCSE 7.0M
- APRE 8.3M
- IPO Year
- JCSE 2022
- APRE 2019
- Fundamental
- Price
- JCSE $1.33
- APRE $1.45
- Analyst Decision
- JCSE
- APRE Strong Buy
- Analyst Count
- JCSE 0
- APRE 1
- Target Price
- JCSE N/A
- APRE $20.00
- AVG Volume (30 Days)
- JCSE 18.3K
- APRE 142.2K
- Earning Date
- JCSE 10-30-2025
- APRE 11-07-2025
- Dividend Yield
- JCSE 7.03%
- APRE N/A
- EPS Growth
- JCSE N/A
- APRE N/A
- EPS
- JCSE 0.00
- APRE N/A
- Revenue
- JCSE $14,126,397.00
- APRE $841,012.00
- Revenue This Year
- JCSE N/A
- APRE N/A
- Revenue Next Year
- JCSE N/A
- APRE N/A
- P/E Ratio
- JCSE $289.31
- APRE N/A
- Revenue Growth
- JCSE 6.92
- APRE N/A
- 52 Week Low
- JCSE $0.86
- APRE $1.31
- 52 Week High
- JCSE $2.07
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- JCSE 54.90
- APRE 46.64
- Support Level
- JCSE $1.30
- APRE $1.31
- Resistance Level
- JCSE $1.35
- APRE $1.49
- Average True Range (ATR)
- JCSE 0.05
- APRE 0.10
- MACD
- JCSE -0.02
- APRE -0.01
- Stochastic Oscillator
- JCSE 57.89
- APRE 36.84
About JCSE JE Cleantech Holdings Limited
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The product lives of its cleaning systems and other equipment ranges from two to ten years. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company derives the majority of its revenue from the Sales of cleaning systems and other equipment. Geographically, the company derives a majority of its revenue from Singapore, followed by Malaysia.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.